Latigo Biotherapeutics, Inc.
LTGO Nasdaq
SEC CIK 2056611
Follow Latigo Biotherapeutics
Weekly email: filings, results
Net income
−$20.9M
+15.5% vs same quarter last year
EPS, diluted
−$0.55
+98.1% vs same quarter last year
Operating cash flow
−$19.5M
+2% vs same quarter last year
Operating income
−$22.9M
+7.3% vs same quarter last year
Source: SEC XBRL filings · latest filing